User:Yma eelyar/sandbox

Genomics Medicine Ireland is a Dublin-based life sciences company co-founded by Daniel Crowley, Sean Ennis, Paul Thurk and Maurice Treacy in 2015. The company has established a scientific database platform to examine the human genome in order to improve understanding of the genetic factors involved in disease with the goal that this will lead to new prevention strategies and treatments.

History
Genomics Medicine Ireland (GMI) was established as a limited company in May 2015. GMI was officially launched by Taoiseach Enda Kenny on 26 October, 2016, in an announcement timed to coincide with the company’s Series A funding round. Investors in the Series A funding round included the Ireland Strategic Investment Fund - part of Ireland’s National Treasury Management Agency (NTMA), GV (formerly Google Ventures), Arch Venture Partners and Polaris Partners.

Activity
In January, 2017, Genomics Medicine Ireland announced a 15-year collaboration with major multinational pharmaceutical group, AbbVie, to map the genomes of 45,000 Irish people in an effort to develop drugs for the future in the areas of cancer, neurosciences and immunology. The company subsequently announced a number of island-wide genetic study areas including rare disorders, GenoFit health and fitness research study, Inflammatory Bowel Disease and Multiple Sclerosis.

Board Members
The Board of Genomics Medicine Ireland includes:
 * 1) Kári Stefánsson, President, Chairman, CEO and co-founder of deCODE Genetics
 * 2) Terry McGuire, co-founder and general partner of Polaris Partners
 * 3) Paul Thurk, Director, Europe with ARCH Venture Partners
 * 4) Tom Hulme, General Partner at GV (Google Ventures)
 * 5) Daniel Crowley, CEO of Genomics Medicine Ireland
 * 6) Paul Saunders, Head of Innovation and Special Investments - ‎Ireland Strategic Investment Fund / NTMA